Abstract

The NKL-code describes normal expression patterns of NKL homeobox genes in hematopoiesis. Aberrant expression of NKL homeobox gene subclass members have been reported in several hematopoietic malignancies including acute myeloid leukemia (AML). Here, we analyzed the oncogenic role of the HMX-group of NKL homeobox genes in AML. Public expression profiling data–available for HMX1 and HMX2—indicate aberrant activity of HMX2 in circa 2% AML patients overall, rising to 31% in those with KMT2A/MLL rearrangements whereas HMX1 expression remains inconspicuous. AML cell lines EOL-1, MV4-11 and MOLM-13 expressed both, HMX2 and neighboring HMX3 genes, and harbored KMT2A aberrations, suggesting their potential functional association. Surprisingly, knockdown experiments in these cell lines demonstrated that KMT2A inhibited HMX2/3 which, in turn, did not regulate KMT2A expression. Furthermore, karyotyping and genomic profiling analysis excluded rearrangements of the HMX2/3 locus in these cell lines. However, comparative expression profiling and subsequent functional analyses revealed that IRF8, IL7- and WNT-signalling activated HMX2/3 expression while TNFa/NFkB- signalling proved inhibitory. Whole genome sequencing of EOL-1 identified two mutations in the regulatory upstream regions of HMX2/3 resulting in generation of a consensus ETS-site and transformation of a former NFkB-site into an SP1-site. Reporter-gene assays demonstrated that both mutations contributed to HMX2/3 activation, modifying ETS1/ELK1- and TNFalpha-mediated gene regulation. Moreover, DMSO-induced eosinophilic differentiation of EOL-1 cells coincided with HMX2/3 downregulation while knockdown of HMX2 induced cell differentiation, collectively supporting a fundamental role for these genes in myeloid differentiation arrest. Finally, target genes of HMX2/3 were identified in EOL-1 and included suppression of differentiation gene EPX, and activation of fusion gene FIP1L1-PDGFRA and receptor-encoding gene HTR7, both of which enhanced oncogenic ERK-signalling. Taken together, our study documents a leukemic role for deregulated NKL homeobox genes HMX2 and HMX3 in AML, revealing molecular mechanisms of myeloid differentiation arrest.

Highlights

  • Acute myeloid leukemia (AML) is a malignant disease characterized by clonal expansion of undifferentiated myeloid precursors

  • HMX1 is normally active in the erythroid branch of myelopoiesis these data provide little support for an oncogenic role in AML [18]

  • According to the reported myeloid NKL-code, six NKL homeobox genes participate in the physiological differentiation of granulocytes, monocytes and macrophages, dendritic cells, and erythrocytes while 24 deregulated members of the NKL subclass are described in AML and myelodysplastic syndrome (MDS) [18]

Read more

Summary

Introduction

Acute myeloid leukemia (AML) is a malignant disease characterized by clonal expansion of undifferentiated myeloid precursors. AML is the most common acute leukemia in the elderly and classified according to chromosomal aberrations [1]. Certain key oncogenic fusion genes retain their peak diagnostic and therapeutic significance. The KMT2A/MLL gene encodes a histone methyltransferase which is aberrantly fused to several partner genes by specific recurrent chromosomal translocations, defining an AML subgroup [1, 4]. In addition to gene fusions, KMT2A gene aberrations comprise amplifications and partial tandem duplications [5]. KMT2A methylates histone H3, generating H3K4me which is associated with gene activation [6]. Key oncogenic KMT2A-targets are transcription factors encoded by the HOXA homeobox gene cluster predominantly expressed at early stages of hematopoiesis [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call